MedTrace Logo

Melatonin Levels on COVID-19 Positive Pregnant Women

NCT05318144 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2022-04-08

No results posted yet for this study

Summary

This study aimed to investigate the prognostic value of serum melatonin as a biomarker for the determination of severe COVID-19 infection in pregnant women.

Four study groups were formed, including pregnant women with a positive COVID-19 PCR test, severe symptoms, and inpatient treatment. Pregnant women who had complaints similar to COVID-19 infection or had no complaints, but had a PCR test due to the surveillance program and negative test results were included in the control group.

Methods and Main Outcome measure: Laboratory values of the cases at the time of diagnosis parameters were collected.

Melatonin levels decrease in pregnant women with COVID-19 symptoms, the severity of symptoms increases. In addition, patients with low melatonin levels have an increase in infection parameters and an increase in the hospital stay.

Conditions

  • COVID-19 Acute Respiratory Distress Syndrome
  • Pregnancy Related
  • Pregnancy Complications

Interventions

OTHER

Sponsors & Collaborators

  • Nazan Yurtcu MD

    lead OTHER

Principal Investigators

  • Serkan Oral · Halic University Faculty of Medicine, Department of Obstetrics and Gynecology

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2021-12-01
Completion
2022-02-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05318144 on ClinicalTrials.gov